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Telomeres, the termini of chromosomes, provide
essential stability to linear eukaryotic chromosomes.
The enzyme telomerase is one mechanism that
maintains telomeres, and is activated in 85% of human
cancer cells. New studies on peptide nucleic acids
(PNAs) that inhibit telomerase have demonstrated that
unexpected regions of the enzyme can serve as targets
for inhibitors. The novel delivery method used expands
the utility of PNAs.
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Human telomerase activity was first detected in the trans-
formed cervical carcinoma cell line HeLa in 1989 [1].
Conventional DNA polymerases and primases cannot
replicate the terminal bases of a linear DNA molecule, so,
in the absence of other mechanisms, chromosomes will
shorten with the removal of terminal RNA primers during
each round of replication [2–4]. Telomerase is an enzyme
that compensates for the loss of telomeric sequences at
the ends of chromosomes by adding tandem repeats of
d(TTAGGG) that make up the telomere. Human telom-
erase is a ribonucleoprotein, consisting of a catalytic
protein subunit, the telomerase reverse transcriptase
component (hTERT), one or more additional proteins,
and an integral RNA component (hTR) that serves as a
template for the synthesis of the telomeric repeats [5].
TERT contains reverse transcriptase (RT) motifs, which
are conserved among reverse transcriptase enzymes, and
telomerase-specific motifs. Conserved amino acids in
both of these sets of motifs are required for catalytic
activity [5–7]. Human telomerase activity can be reconsti-
tuted in vitro by expressing hTERT and hTR in rabbit
reticulocyte lysate [8,9].
Telomerase, immortalization and cancer
In the last ten years evidence has accumulated correlating
telomerase activity with cell immortalization and cancer
[3,10]. In most cultured primary somatic human cells,
telomerase is inactive: telomeres shorten upon cell divi-
sion and the cells eventually undergo replicative senes-
cence. Human germ cells, which are telomerase positive,
have long telomeres. But many established, immortalized
cell lines also express telomerase activity, and have short
telomeres that are generally maintained at a constant
length as the cells are passaged [11]. Telomerase activity
has been detected in over 85% of tumor samples tested
[12]. The idea that telomerase may be required to main-
tain telomeres and stabilize chromosomes in many immor-
talized cells, and that its inactivation may specifically
inhibit the proliferation of cancer cells, has, therefore,
been gaining ground. However, there are a number of
issues to consider in attempting to develop specific anti-
telomerase therapies directed against cancer cells [10,13].
Three of these are listed below.
First, 15% of immortal and tumor cells have no detectable
telomerase activity. Conversely, activity has been reported
in some human somatic tissues, including hematopoietic
and epithelial cells [3]. Antitelomerase therapies are
unlikely, therefore, to be universally effective and may
have side effects. 
Second, telomerase inhibition via telomere shortening
would not be expected to have immediate adverse effects,
especially in tumor cells that do not already have
extremely short telomeres. In mice, deletion of the telom-
erase RNA component resulted in the loss of telomeres
and end-to-end fusion of chromosomes, but only in the
fourth generation [14]. Six to seven generations were
required before the mice developed abnormal pheno-
types, which included defective spermatogenesis and
decreased proliferation in testis and hematopoietic cells of
the bone marrow and spleen [15] (Table 1). Because mice
have longer telomeres than humans, this lag may not be so
profound in humans, but most telomerase inhibitors do
have a lag phase before a phenotypic effect is apparent
[13]. However, two telomerase inhibitors have been
described that cause immediate cell death, perhaps by
triggering cell cycle arrest, so the development of telom-
erase inhibitors that manifest early secondary effects may,
after all, be possible [13,16,17]. There have also been
reports that anti-telomerase therapy could be used in com-
bination with chemotherapy to treat certain cancers resis-
tant to conventional chemotherapy [18].
Third, resistance to telomerase inhibitors may be possible.
In yeast, deletion or mutation of the genes encoding the
telomerase RNA, catalytic or associated subunits of telom-
erase lead to telomere shortening, eventual death of most
of the population, and the selection of survivors. These sur-
vivors have rescued telomere lengths or circularized chro-
mosomes as a result of recombination-based, alternative
telomere maintenance mechanisms [3,19–21] (Table 1).
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Alternative mechanisms of telomere lengthening also exist
in humans [22]. Mechanisms of drug resistance are also
likely to include mutations that decrease inhibitor binding
or that upregulate telomerase expression [13].
Telomerase inhibition
Despite these concerns, there is evidence that telomerase
inhibition could, in principle, lead to effective cancer
treatments. Tetrahymena cells expressing mutant telom-
erase RNAs, like yeast telomerase RNA knockouts, show
altered telomere sequences and lengths, resulting in
eventual cell death (Table 1) [23]. Similarly, the identifi-
cation of the RNA component of human telomerase in
1995 [24] led to a growing number of reports of inhibition
of human telomerase in a variety of experimental circum-
stances: in vitro, in cultured cells, and in vivo using
xenograft human-mouse models (Table 2). The expres-
sion of antisense telomerase RNA in immortal human
cells leads to telomere shortening and cell death [24].
These inhibitors generally target the template region of
the RNA component of telomerase (hTR), the telomerase
active site, the catalytic component of telomerase
(hTERT), or G-quartet DNA structures [25–28]. 
Targeting telomerase activity carries the risk of inadver-
tently inhibiting other polymerases. Nucleoside analogs
(and their triphosphate derivatives), such as azido-
thymidine that inhibit polymerases such as HIV reverse
transcriptase, have also been used to inhibit telomerase,
but have limited specificity and potency [25,29–33].
Several oligonucleotide derivatives have been tested as
telomerase inhibitors, including DNA, phosphorothioate
(PS) oligonucleotides, peptide nucleic acids (PNAs) and
2′-O-methyl (2′-O-me) RNAs (Figure 1). Hammerhead
ribozymes have also been designed to cleave hTR
[27,34,35]. Another approach is to target G-quadruplexes,
structures that can be adopted by single-stranded G-rich
regions, such as those found at the ends of chromosomes
[36]. It has been postulated that such structures form at
chromosome ends and that these structures are essential
for proper telomerase function; several molecules that bind
to G quartets have been identified that inhibit telomerase
activity [26,37,38]. However, such molecules can bind
both to DNA and RNA, reducing their specificity [13], and
may also inhibit processes involved in immunoglobulin
gene rearrangement and transcriptional regulation [38].
Directly targeting the catalytic protein component,
hTERT, instead of the RNA component, hTR, may be
more effective, as telomerase activity correlates best with
the expression of hTERT [39]. In humans, hTR is
detectable not only in immortal cancer cell lines, tumors
and tissues that express telomerase activity, but also in
cell lines, tumors and tissues that do not have telomerase
activity [24,40]. In contrast, hTERT is expressed in all
telomerase-positive cells and in only a specific subset of
telomerase-negative cells thought to have long-term pro-
liferative capacity [41]. However, to date, the only
reported telomerase inhibitor that targets hTERT is the
expression of a mutant catalytic subunit of human telom-
erase [42,43]. The effects of inhibiting hTERT by the
expression of dominant negative mutants of hTERT
include the inhibition of telomerase activity, telomere
loss, chromosome damage, apoptosis and cell death of
various human cancer cell lines [42,43]. 
Selectivity of telomerase inhibitors
One particularly interesting class of anti-hTR telomerase
inhibitors is the PNAs [44], which give the highest specific
in vitro inhibition of telomerase activity known [28,45,46].
Compared with standard oligonucleotides or PS oligonu-
cleotides, PNAs bind to targeted RNA more rapidly and
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Table 1
Phenotype of telomerase alterations in various organisms.
Organism Alteration Phenotype(s) References
Tetrahymena Mutant RNA template Altered telomere sequence and length; nuclear and cell division defects; [23,48]
thermophila sequences senescence
Saccharomyces cerevisiae ∆TLC1 Telomere shortening; a gradual increase in generation time; cell death; [19,20]
Kluyveromyces lactis ∆TER1 survivors have rescued telomere lengths
Schizosaccharomyces ∆TRT1 Loss of telomeric DNA and viability; survivors have maintained telomeres [21]
pombe or circularized chromosomes
Human Expression of antisense Decreased telomere lengths; decreased telomerase activity; cell death [24]
hTR in immortal cells
Human Expression of hTERT in Telomerase expression; telomere lengthening; extension of life span [49]
normal human cells
Mouse Telomerase RNA gene Telomere shortening; loss of telomeres, end-to-end fusions, aneuploidy [14,15]
knockout (generation four); defective spermatogenesis, decreased proliferation in
testis and haematopoitic cells of bone marrow and spleen (generation six)
TLC1, TER1 and TRT1 are the genes encoding the telomerase RNA components of S. cerevisiae and K. lactis, and the catalytic component of
S. pombe, respectively. 
with higher affinity and specificity.  The lack of a phos-
phate backbone decreases electrostatic interactions, pre-
venting PNAs from associating with proteins that normally
bind nucleic acids. IC50 values for the inhibition of telom-
erase by PNAs complementary to the template of hTR are
in the picomolar to nanomolar range, whereas IC50 values
are in the micromolar range for noncomplementary PNAs.
PS oligomers show lower activity and lower selectivity; the
IC50 of complementary versus noncomplementary PS
oligonucleotides is 50 and 100 µM, respectively, probably
a result of nonsequence selective protein binding by PS
oligomers [28]. A further advantage of PNAs is their resis-
tance to degradation by both proteases and nucleases. 
Very recently, David Corey and colleagues [45] elegantly
demonstrated that PNAs directed to regions of hTR other
than the template provide a new mode of inhibition, pre-
sumably acting prior to the assembly of the ribonucleopro-
tein. Initially, PNAs directed against nontemplate regions
of hTR did not demonstrate significant inhibition in cell
extracts [28]. But by separately expressing hTERT and
hTR in a rabbit reticulocyte transcription and translation
system, Corey and colleagues [45] were able to determine
the effect of inhibitors on assembly of the telomerase.
IC50 values for six PNAs directed against different non-
template regions of hTR were between 10 and 100 nM
when the PNAs were added prior to hTERT expression.
After the telomerase holoenzyme had been assembled,
the same PNAs gave IC50 values of 2 to > 100 µM, indicat-
ing that the targets for these PNAs are not readily accessi-
ble once hTR has associated with hTERT. When added
before telomerase assembly, PNAs targeted to the hTR
template region inhibited the telomerase with IC50 values
of 0.02–0.1 µM, increasing to 0.03–0.5 µM when the
holoenzyme was used; as expected, therefore, the tem-
plate region of hTR is the most accessible portion of the
RNA after the holoenzyme is assembled. Using these
anti-template PNAs, and an ingenious adaptation of the
standard cationic lipid transfection technique to introduce
partially overlapping PNA–DNA duplexes into cells,
Corey and colleagues [45] show that over 85% inhibition
of telomerase activity can be achieved in the DU145
prostate cancer cell line. Inhibition can also be achieved
in whole cells even when the PNAs are targeted to non-
template regions; a longer transfection of nontemplate-
directed PNAs led to 84% inhibition of telomerase
activity in one case, and 78% inhibition in another. These
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Table 2
Telomerase inhibition.
Inhibitor IC50 Proposed target References
Expression of antisense RNA NA hTR [17,24,50,51]
Retroviral antisense NA hTR [52]
Nucleoside derivatives: AZT-TP, 7-deaza-dATP, 1–30 µM Telomerase active site [25,29–33]
7-deaza-dGTP, ddGTP, Gp4G
Phosphorothioate DNA 200pM– < 25 µM hTR/hTERT [16,28,53–56]
Phosphodiester DNA oligos 20–100 nM hTR [33,57]
Oligonucleotide with 2′-5′- oligoadenylate linkage ND hTR/RNase L-mediated [17]
Peptide nucleic acid (PNA) 900 pM–100 µM hTR [28,45,46]
PNA–cationic peptide conjugates 140 nM– > 8 µM hTR [58]
2′-O-methyl RNA 2–300 nM hTR [47]
Hammerhead ribozymes 400 nM–10 µM hTR [27,34,35]
Anthraquinone derivatives 4–50 µM G-quadruplex [26,59]
Cationic porphyrin ≤ 50 µM G-quadruplex [37,60]
Perylenetetracarboxylic diimide > 75 µM G-quadruplex [38]
Cisplatin 2 µM hTR transcription [61]
NA, not applicable; ND, not determined. 
Figure 1
Chemical structures of (a) DNA, (b) PS oligonucleotides,
(c) 2′-O-methyl RNAs and (d) PNA.
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nontemplate-directed PNA inhibitors represent a new
class of telomerase inhibitors, and perhaps indicate new
possible targets for non-PNA telomerase inhibitors. 
The adapted transfection method used in this study was
also previously used for the intracellular delivery of
2′-O-me RNA telomerase inhibitors [47], and should find
wide use in studies of the cellular activities of PNAs. By
using overlapping PNA–DNA hybrids instead of comple-
mentary ones, the authors expected to be able to use the
DNA as a carrier, then allow the DNA to be digested by
nucleases inside the cells. The PNA would then be free to
bind to its target. Microscopy and fluorescence-activated
cell sorter analysis were used to confirm that rhodamine-
labelled PNAs were indeed delivered into the cells with
high efficiency. None of the PNA–DNA hybrids tested
were immediately toxic, and the telomerase inhibition
persisted for three population doublings, indicating that
the amount of PNA that is delivered to the cells is suffi-
cient to withstand the dilution caused by segregation
during cellular division. After a four-week treatment
telomere shortening was observed, confirming the speci-
ficity of the PNA inhibitors. Furthermore, nontemplate-
hTR-directed PNAs inhibited telomerase activity to levels
comparable with template-directed PNAs (upon increased
time of incubation with cells), substantiating the in vitro
observation that these PNAs may affect telomerase
ribonucleoprotein assembly in actively dividing cells. 
Conclusions and future perspectives
The discovery that PNAs directed against nontemplate
regions of the human telomerase RNA can be potent
telomerase inhibitors [45] offers a new set of targets for
exploration and opens up the possibility that combinations
of telomerase inhibitors could be used. Furthermore, the
ability to effectively introduce PNAs into eukaryotic cells
using a simple method and the efficient inhibition of cellu-
lar telomerase by PNAs has overcome one major difficulty
for PNA research, and may have profound implications in
the development of specific and potent antitelomerase
cancer therapies. The question of whether PNAs can be
used as effective anti-proliferative agents remains, how-
ever, to be demonstrated. This next step in the develop-
ment of telomerase inhibitors will determine if targeting
telomerase as an anticancer therapy will indeed be possible. 
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